Montreal/June 23, 2022 – NexPlasmaGen is honored to present at the MedInvest Oncology Investor Conference.
The MedInvest Oncology Investor Conference will be hosted in person June 28-29, 2022 in New York...
NEXPLASMAGEN TO PRESENT AT THE 2022 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/January 30, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2022 OBIO Investment...
NEXPLASMAGEN TO PRESENT AT SEED SHOWCASE 2022
NexPlasmaGen will pitch its business opportunity to investors!
Montreal/December 24 – NexPlasmaGen, today announced that it is presenting at Seed Showcase, part of the Biotech...
NexPlasmaGen is proud to announce that the preclinical trials program led by Dr. Philip Wong at the Centre Hospitaller de l’Université de Montréal was successfully completed. The first stage of...
NexPlasmaGen Inc. is pleased to announce that its patented cold plasma technology is in preparation for clinical investigation for the treatment of breast cancer. NexPlasmaGen has recently received financial support...
NexPlasmaGen Inc. is pleased to announce the completion of $795,000 in private and public investment from individuals, Aligo Innovation, the Quebec MEDTEQ program and the federal MITACS and CNRC-IRAP programs...